A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 12 Feb 2019 Status changed from not yet recruiting to recruiting.
- 14 Jan 2019 Planned End Date changed from 1 Jan 2020 to 1 May 2020.
- 14 Jan 2019 Planned primary completion date changed from 1 Jan 2020 to 1 May 2020.